Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Spectral analysis of heart rate variability in patients with newly diagnosed atrial fibrillation
https://doi.org/10.33667/2078-5631-2024-13-42-46
Abstract
Spectral analysis of heart rate variability gives an idea of the role of the autonomic nervous system in the regulation of chronotropic heart function and can be used to evaluate the effectiveness of drug therapy. The selection of drug therapy taking into account the individual clinical form of atrial fibrillation, as well as the vegetative status of the patient, will undoubtedly increase the effectiveness of treatment. In this study, spectral parameters were studied in patients with newly diagnosed atrial fibrillation and the effect of the antiarrhythmic drug class III miodarone on these parameters.
About the Authors
O. T. Bogova
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Bogova Olga T. - DM Sci (habil.), associate professor, professor at Dept of Geriatrics and Medical and Social Expertize, SCOPUS Author ID: 57204687262. Researcher ID: F-6450-2019.
Moscow
A. V. Sviridenko
Mositalmed Clinic
Russian Federation
Russian Federation
Sviridenko Anna V. - cardiologist and functional diagnostic.
Moscow
V. N. Potapov
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Potapov Vladimir N. - DM Sci (habil.), associate professor, professor at Dept of Geriatrics and Medical and Social Expertize.
Moscow
References
1. Orlova N. V., Fedulaev Yu. N. School of health for patients with atrial fibrillation CardioSomatics. 2019; 10 (3): 50–59. (In Russ.).
2. Achkasov E. E., Mashkovsky E. V., Bogova O. T., Puzin S. N., Sultanova O. A. Myocardial remodeling in ischemic heart disease in sports veterans. Medico-social expertise and rehabilitation. 2013; 4: 10–14. (In Russ.).
3. Bogova O. T. Features of management of patients with coronary heart disease in diabetes mellitus: Textbook, RMANPO, FIRO Publishing House, Moscow, 2016. 117 p. (In Russ.).
4. Popova E. P., Bogova O. T., Puzin S. N. et al. The effect of antiarrhythmic drugs on the spectral parameters of heart rate variability in patients with atrial fibrillation. Medical and Social Expertise and Rehabilitation. 2018; 21 (1–2): 101–104. (In Russ.).
5. Popova E. P., Bogova O. T., Chandirli S. A., Puzin S. N., Sychev D. A., Fisenko V. P. The effect of amiodarone on heart rate variability in elderly and senile patients with different forms of atrial fibrillation. Successes of gerontology. 2019; 32 (6): 1011–1016. (In Russ.).
6. Popova E. P., Bogova O. T., Puzin S. N., Fisenko V. P. The importance of the autonomic nervous system in the pathogenesis of atrial fibrillation. Russian Journal of Cardiology. 2020; 25 (7): 187–193. (In Russ.). DOI: 10.15829/1560–4071–2020–3663
7. Puzin S. N., Bogova O. T., Odebaeva R. et al. Rehabilitation of patients with coronary heart disease. Bulletin of the All-Russian Society of Specialists in Medical and Social Expertise, rehabilitation and rehabilitation industry. 2014; 2: 6–9. (In Russ.).
8. Puzin S. N., Shurgaya M. A., Chandirli S. A., Bogova O. T., Potapov V. N.R., Tairov G. M. Aspects of medical and social rehabilitation of patients with hypertension. Medical and social expertise and rehabilitation. 2014; 1: 10–15. (In Russ.).
9. Puzin S. N., Grashchenkova A. N., Bogova O. T. Rehabilitation of patients who have suffered a myocardial infarction on an outpatient basis. Medical Alphabet. 2020; 2: 52–53. (In Russ.).
10. Sychev D. A., Zhuchkov A. V., Bogova O. T., Ilyina E. S. Falls of elderly and senile patients: contribution of medicines. Clinical gerontology. 2017; 23 (3–4): 56–64. (In Russ.).
11. Baevsky R. M., Ivanov I. I. et al. Analysis of heart rate variability using different electrocardiographic systems (guidelines). Vestnik Aritmologii. 2001; 24: 65–87. (In Russ.).
12. Bogova O. T., Sviridenko A. V., Puzin S. S., Markova A. S., Puzin S. N. The effect of amiodarone on spectral parameters of heart rate variability in patients with various forms of atrial fibrillation. J. Medical Alphabet Series Modern polyclinic 2. 2023; 26 (555): 41–45. (In Russ.). DOI: 10.33667/2078–5631–2023–26–41–45
13. Iskenderov B. G., Rahmatulov F. K. Structural and electrophysiological parameters of cardiac function in paroxysmal atrial fibrillation. Ter archive. 2001; 12: 52–56. (In Russ.).
14. Fleishman A. N., Filimonov S. N., Klimina N. V. A new method of selecting drugs for the treatment of arterial hypertension based on spectral analysis of heart rate variability. Ter. Archive. 2001; 12: 33–39. (In Russ.).
15. Chukaeva I. I., Orlova N. V., Khachirova A. I. and others. Gender differences in arterial wall stiffness in patients with arterial hypertension and high total cardiovascular risk. Bulletin of Modern Clinical Medicine. 2014; 7 (3): 35–38. (In Russ.).
16. Task Forse of the European Society of Cardiology and the North American Society of Paciety of Pacing and Electrophysiology. Heart rate variability. Standarts of measurements, physiological interpretation and clinical use. Circulation. 1996; 93: 1043–1065.
17. Akselrod S., Eds M. Malik, A. J. Camm. Components of heart rate variability. Basis studies. In: Heart Rate Variability. Armonk. N.-Y. Futura Pablishity. Comp. Inc. 1995. Р. 147–163.
18. Lok N.S., Lau C. P. Abnormal vasovagal reaction, autonomic function, and heart rate variability in patients with paroxysmal atrial fibrillation. Pacing Clin. Electrophysiol. 1998; 21 (2): 386–395. DOI: 10.1111/j.1540–8159.1998.tb00062.x
19. Gal P., Elvan A., Rossi P. et al. Effect of parasympathetic nerve stimulation on atrial and atrioventricular nodal electrophysiological characteristics. Int. J. Cardiol. 2016; 205: 83–85. DOI: 10.1016/j.ijcard.2015.12.027
20. Hanley C.M., Robinson V. M., Peter R. Kowey P. R. Status of Antiarrhythmic Drug Development for Atrial Fibrillation. New Drugs and New Molecular Mechanisms. // Circ. Arrhythm Electrophysiol. 2016; 9 (3): 1–9. DOI: 10.1161/CIRCEP.115.002479
21. Hohendanner F., Heinzel F. R., Blaschke F. et al. Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure. Heart Fail Rev. 2018; 23 (1): 27–36. DOI: 10.1007/s10741–017–9657–9
22. Kirchhof P., Breithardt G., Bax J. et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network. European Heart Rhythm Association consensus conference. Europace. 2016; 18 (1): 37–50. DOI: 10.1093/europace/euv304
23. Patel P.A., Ali N., Hogarth A., Tayebjee M. H. Management strategies for atrial fibrillation. J. R. Soc. Med. 2017; 110 (1): 13–22. DOI: 10.1177/0141076816677857
24. Stavrakis S., Humphrey M. B., Scherlag B. J. et al. Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation. J. Am. Coll. Cardiol. 2015; 65: 867–75. DOI: 10.1016/j.jacc.2014.12.026
25. Wang Z., Page P., Nattel S. Mechanism of flecainide’s antiarrhythmic action in experimental atrial fibrillation. Circ. Res. 1992; 71(2): 271–287. DOI: 10.1161/01.res.71.2.271
Review
For citations:
Bogova O.T., Sviridenko A.V., Potapov V.N. Spectral analysis of heart rate variability in patients with newly diagnosed atrial fibrillation. Medical alphabet. 2024;(13):42-46. (In Russ.) https://doi.org/10.33667/2078-5631-2024-13-42-46
Views:
524
Email this article 